Uveal melanoma dormancy: An acceptable clinical endpoint?

Melanoma Research

Volumn 22, Issue 5, 2012, Pages 334-340

  Blanco, Paula L ^a   Lim, Li Anne ^a   Miyamoto, Cristina ^a   Burnier, Miguel N ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

circulating malignant cells; metastasis; tumor dormancy; uveal melanoma

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ANGIOGENESIS; ANTIGEN EXPRESSION; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CELL CYCLE ARREST; CHROMOSOME 3; CHROMOSOME ABERRATION; DISTANT METASTASIS; DORMANCY; ENUCLEATION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOSURVEILLANCE; LIFE EXPECTANCY; METASTASIS; MITOSIS RATE; MORBIDITY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; UVEA MELANOMA;

ANIMALS; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; ENDPOINT DETERMINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; NEOPLASTIC CELLS, CIRCULATING; UVEAL NEOPLASMS;

EID: 84866260326     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328357bea8     Document Type: Review

References (75)

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664-1678. (Pubitemid 28465486)
2. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118:1881-1885.
3. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32: 239-251. (Pubitemid 18066234)
4. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:956-961. (Pubitemid 36560496)
5. Shields JA, Shields CL. Posterior uveal melanoma: clinical and pathologic features. In: Shields JA, Shields CL, editors. intraocular tumors: a text and atlas Philadelphia: WB Saunders. 1992. pp. 117-136.
6. Singh AD, Shields CL, De Potter P, Shields JA, Trock B, Cater J, Pastore D. Familial uveal melanoma. Clinical observations on 56 patients. Arch Ophthalmol 1996; 114:392-399. (Pubitemid 26118057)
7. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222-1225. (Pubitemid 26131850)
8. Sisley K, Parsons MA, Garnham J, Potter AM, Curtis D, Rees RC, Rennie IG. Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer 2000; 82:330-338. (Pubitemid 30045378)
9. Patel KA, Edmondson ND, Talbot F, Parsons MA, Rennie IG, Sisley K. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol 2001; 85:1440-1444. (Pubitemid 34032910)
10. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 1997; 19:22-28. (Pubitemid 27193716)
11. Harbour JW. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res 2012; 25:171-181.
12. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol 1990; 108: 1268-1273.
13. Mclean IW, Burnier MN, Zimmerman LE, Jakobiec FA. Tumors of the uveal tract. Atlas of tumor pathology-tumors of the eye and ocular adnexa. Washington: Armed Forces Institute of Pathology (AFIP). 1993. pp. 161-194.
14. Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 2007; 114:1925-1931.
15. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci 2009; 50:3048-3055.
16. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010; 12:461-468.
17. Onken MD,Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64:7205-7209. (Pubitemid 39372052)
18. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative Ocular Oncology Group. Report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119:1596-1603.
19. Boldin I, Langmann G, Richtig E, Schwantzer G, Ardjomand N,Wegscheider B, El-Shabrawi Y. Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. Melanoma Res 2005; 15:503-507. (Pubitemid 44124261)
20. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clini Cancer Res 2007; 13:1171-1178. (Pubitemid 46424057)
21. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Thiel E, et al. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology 2011; 80:57-62.
22. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye (Lond) 2007; 21:752-759. (Pubitemid 46909176)
23. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123:1639-1643. (Pubitemid 41785095)
24. Marshall JC, Nantel A, Blanco P, Ash J, Cruess SR, Burnier MN Jr. Transcriptional profiling of human uveal melanoma from cell lines to intraocular tumors to metastasis. Clin Exp Metastasis 2007; 24:353-362. (Pubitemid 47124936)
25. Blanco PL, Marshall JC, Antecka E, Callejo SA, Souza Filho JP, Saraiva V, Burnier MN Jr. Characterization of ocular and metastatic uveal melanoma in an animal model. Invest Ophthalmol Vis Sci 2005; 46:4376-4382. (Pubitemid 44264529)
26. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-20-deoxyuridine. J Natl Cancer Inst 1970; 45:773-782.
27. De Croock L, Verbraeken H. Metastatic uveal melanoma: diagnosis and treatment. A literature review. Bull Soc Belge Ophtalmol 2002; 286:59-63.
28. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119:670-676.
29. McLean IW. The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat Histopathol 1993; 422:433-437. (Pubitemid 23223657)
30. Manschot WA, Lee WR, van Strik R. Uveal melanoma: updated considerations on current management modalities. Int Ophthalmol 1995; 19:203-209. (Pubitemid 26000312)
31. Shields JA, Shields CL, Donoso LA. Management of posterior uveal melanoma. Surv Ophthalmol 1991; 36:161-195.
32. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000; 107: 1443-1449.
33. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294:139-146.
34. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009; 69:836-844.
35. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Investigat 2010; 120:2030-2039.
36. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010; 11:790-796.
37. Naumov GN, Townson JL, MacDonald IC,Wilson SM, Bramwell VH, Groom AC, Chambers AF. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003; 82:199-206. (Pubitemid 37521976)
38. Townson JL, Ramadan SS, Simedrea C, Rutt BK, MacDonald IC, Foster PJ, Chambers AF. Three-dimensional imaging and quantification of both solitary cells and metastases in whole mouse liver by magnetic resonance imaging. Cancer Res 2009; 69:8326-8331.
39. Vessella RL, Pantel K, Mohla S. Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther 2007; 6:1496-1504. (Pubitemid 351590364)
40. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148:119-127.
41. Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992; 36: 429-438.
42. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978; 135:807-810. (Pubitemid 8377329)
43. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999; 9:575-581. (Pubitemid 30007776)
44. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clini Cancer Res 2008; 14:951-956. (Pubitemid 351302538)
45. Burnier JV, Wang N, Michel RP, Hassanain M, Li S, Lu Y, et al. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene 2011; 30:3766-3783.
46. Shoushtari AN, Szmulewitz RZ, Rinker-Schaeffer CW. Metastasissuppressor genes in clinical practice: lost in translation? Nat Rev Clin Oncol 2011; 8:333-342.
47. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3:55-63. (Pubitemid 37328887)
48. Palmieri D, Horak CE, Lee JH, Halverson DO, Steeg PS. Translational approaches using metastasis suppressor genes. J Bioenerg Biomembr 2006; 38:151-161. (Pubitemid 44946222)
49. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998; 16:1097-112. (Pubitemid 28127509)
50. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316:1160-1166. (Pubitemid 46877472)
51. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008; 68:6953-6962.
52. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010; 465:243-247.
53. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43:1022-1025.
54. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43:1018-1021.
55. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011; 48:856-859.
56. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410-1413.
57. Yamaguchi A, Urano T, Fushida S, Furukawa K, Nishimura G, Yonemura Y, et al. Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis. Br J Cancer 1993; 68:1020-1024. (Pubitemid 23315242)
58. Tokunaga Y, Urano T, Furukawa K, Kondo H, Kanematsu T, Shiku H. Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer 1993; 55:66-71. (Pubitemid 23261708)
59. Wang YF, Chen JY, Chang SY, Chiu JH, Li WY, Chu PY, et al. Nm23-H1 expression of metastatic tumors in the lymph nodes is a prognostic indicator of oral squamous cell carcinoma. Int J Cancer 2008; 122:377-386.
60. Ma D, Luyten GP, Luider TM, Jager MJ, Niederkorn JY. Association between NM23-H1 gene expression and metastasis of human uveal melanoma in an animal model. Invest Ophthalmol Vis Sci 1996; 37:2293-2301. (Pubitemid 26338778)
61. Bakalian S, Marshall JC, Faingold D, Logan P, Antecka E, Burnier MN Jr. Expression of nm23-H1 in uveal melanoma. Melanoma Res 2007; 17: 284-290. (Pubitemid 47462220)
62. Martin TA,Watkins G, Jiang WG. KiSS-1 expression in human breast cancer. Clin Exp Metastasis 2005; 22:503-511. (Pubitemid 41750702)
63. Marot D, Bieche I, Aumas C, Esselin S, Bouquet C, Vacher S, et al. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. Endocr Relat Cancer 2007; 14:691-702. (Pubitemid 350074058)
64. Nagai K, Doi R, Katagiri F, Ito T, Kida A, Koizumi M, et al. Prognostic value of metastin expression in human pancreatic cancer. J Exp Clin Cancer Res 2009; 28:9.
65. Shengbing Z, Feng LJ, Bin W, Lingyun G, Aimin H. Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma. Anat Rec (Hoboken) 2009; 292:1128-1134.
66. Dhar DK, Naora H, Kubota H, Maruyama R, Yoshimura H, Tonomoto Y, et al. Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. Int J Cancer 2004; 111:868-872. (Pubitemid 39096235)
67. Wang H, Jones J, Turner T, He QP, Hardy S, Grizzle WE, et al. Clinical and biological significance of KISS1expression in prostate cancer. Am J Pathol 2012; 180:1170-1178.
68. Sanchez-Carbayo M, Capodieci P, Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol 2003; 162:609-617. (Pubitemid 36267867)
69. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM,Weissman BE,Welch DR. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996; 88:1731-1737. (Pubitemid 26405010)
70. Nash KT, Welch DR. The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci 2006; 11:647-659. (Pubitemid 43258169)
71. Martins CM, Fernandes BF, Antecka E, Di Cesare S, Mansure JJ, Marshall JC, Burnier MN Jr. Expression of the metastasis suppressor gene KISS1 in uveal melanoma. Eye (Lond) 2008; 22:707-711. (Pubitemid 351712371)
72. Pereira PR, Odashiro AN, Marshall JC, Correa ZM, Belfort R Jr., Burnier MN Jr. The role of c-kit and imatinib mesylate in uveal melanoma. J Carcinog 2005;4-19.
73. Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 2009; 15:324-329.
74. Mouriaux F, Kherrouche Z, Maurage CA, Demailly FX, Labalette P, Saule S. Expression of the c-kit receptor in choroidal melanomas. Melanoma Res 2003; 13:161-166. (Pubitemid 36583978)
75. Fernandes BF, Di Cesare S, Neto Belfort R, Maloney S, Martins C, Castiglione E, et al. Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma. Anal Cell Pathol (Amst) 2011; 34:123-130.